In acute myeloid leukemia (AML), <i>CCR2</i> on <i>CD62L</i> <sup>+</sup> myeloid dendritic cells (DCs) was associated with lower risk, whereas <i>BAFF-R</i> and <i>CD19</i> on transitional B cells were associated with higher risk, <i>CD19</i> on IgD<sup>-</sup>CD38^dim B cells was associated with chronic myeloid leukemia (CML), and HLA-DR<sup>+</sup> NK cells were protective in non-Hodgkin lymphoma (NHL). This evidence concerns the gene SELL and chronic myelogenous leukemia, BCR-ABL1 positive.